Skip to main content
Shingles rash - Join a vaccine study for shingles or culebrilla

Shingles is also known as the “Belt of Fire”.

What is the purpose of this clinical research study?

The goal of this study is to develop a shingles vaccine with a better safety profile, production yields, and equivalent effectiveness to that of the leading vaccine on the market. Essentially, the vaccine being developed is for the prevention of shingles, also known as herpes zoster.  Shingles is a viral disease by the varicella virus, the same virus that causes chickenpox.

Ages

Over 50

Study Topics

Vaccine

Do You Qualify?

Are you over the age of 50?



Have you had previously received a shingles vaccine?



Have you had shingles before?



You Qualify!

Tell us a little about yourself so that we can follow up with you.
First Name*
Last Name*
Email*
Phone*
ZIP Code*
Best time to call
Age*
Sex*
Race*
How did you hear about us?
Questions/Comments

Thank You!

Your information has been submitted. Please check your inbox, spam/junk folders for an email from us. We will contact you shortly, or please call (954) 289-9244 to inquire about the status of your application.

What is Shingles?

Shingles (Herpes Zoster) is a painful blistering skin rash caused by a reactivation of  the varicella-zoster virus VZV. Shingles rash on the face near the eye can cause vision loss and other neurological problems. About 1 in 10 people with Shingles develop nerve pain, called postherpetic neuralgia (PHN) that does not go away for months or even years after the rash has resolved. In individuals with a weakened immune system, reactivation of VZV can be very serious and in some cases, life-threatening.

Study Eligibility Criteria

Ages 50 and over

Participants that have not already had a shingles vaccines

Participants that have not already had a shingles

Do You Not Meet the Criteria for This Study?

You could still participate in other studies. Contact us to be added to our database and you’ll be notified about our future studies that may be right for you.